The Latest Breaking News from Vaccine

The United States should replace most of its COVID-19 booster shots with updated versions that target the dominant omicron strains, an influential group of vaccine experts that advises the Centers for Disease Control and Prevention said Thursday.

Moderna’s shot will be available to adults 18 and older, and Pfizer’s will be available to individuals 12 and older.

The U.S. Food and Drug Administration (FDA) has granted orphan drug designation for Intellia Therapeutics’ (NASDAQ:NTLA) lead asset NTLA-2002, for the treatment of hereditary angioedema (HAE). Intellia shares traded in a range of $56.52 to $60.06 on day volume of 901.43 thousand shares, closed regular trading session at $59.97. The company…

CDC Director Rochelle Walensky has signed off on updated versions of the Moderna and Pfizer-BioNTech vaccines that target the original virus and the omicron subvariants.

A jump in the number of deaths among children in Europe could be caused by numerous factors, experts said, but vaccines are not to blame.

CERVAVAC, India’s first indigenously developed vaccine to prevent cervical cancer, has been developed by SII

“We very much are going to want people to get this updated vaccine right now and not wait three or four months,” she said.

Germany can next week start using COVID-19 vaccines which have been adapted for the Omicron variant and got approval for use in the European Union on Thursday, Health Minister Karl Lauterbach said.

Government advisers are debating who should should get new updated COVID-19 boosters and when

The European Union’s drug regulator has recommended the use of two Omicron-tailored vaccines developed by the Pfizer-BioNTech partnership and Moderna Inc ahead of a fresh booster programme this fall across the continent.

Key Takeaways: The CEO of Everest Medicines resigned two days after the company announced its loss grew sharply in the first half of the year The company also lost an important potential new revenue source after transferring rights for one of its core products to another company By Emily Chan